bullish
SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan
658 Views15 Apr 2022 13:29
SUMMARY
- SanBio Co Ltd (4592 JP) is expected to receive approval for its first regenerative cell medicine SB623 for treating chronic motor deficit from traumatic brain injury in Japan this year.
- SB623, with current and future indication approvals, is targeting a large patient population of more than 50 million in major pharmaceutical markets globally. The indications have large unmet need.
- SanBio has a pipeline of five other pre-clinical drug candidates, entailing visibility beyond SB623.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- SanBio Co Ltd (4592 JP): Conditional Approval for First Drug; Still a Long Way to Go20 Sep 2024
- SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY2417 Mar 2023
- SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily02 Nov 2022
- SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan15 Apr 2022
x